by Raynovich Rod | Jul 29, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 7/30 at close- -Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen: ACAD down 4.08%, ALNY down 7.37%,...
by Raynovich Rod | Jul 22, 2018 | Biopharmaceuticals
7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9% to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock...
by Raynovich Rod | Jul 17, 2018 | Biopharmaceuticals
Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck...
by Raynovich Rod | Jul 9, 2018 | Biopharmaceuticals
Update-2 …Futures Sink As Trade War Rhetoric Heats Up: China Responds to Trump Additional $200B in tariffs on Chinese goods that may get hit with tariffs-See Bloomberg updates. China will take countermeasures-strongly opposed US action. Nikkei hit hardest down...
by Raynovich Rod | Jul 7, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late...
by Raynovich Rod | Jun 30, 2018 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a...
by Raynovich Rod | Jun 21, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Momentous Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170...
by Raynovich Rod | Jun 19, 2018 | Biopharmaceuticals, Clinical Diagnostics and Tools
Rayno Life Science Portfolio FMI: Personalized Medicine for Oncology We are on vacation this week but need to update you on Roche (RHHBY) complete buyout of Foundation Medicine (FMI) one of our top picks in personalized medicine for oncology. FMI is up 28% to $136.50...
by Raynovich Rod | Jun 13, 2018 | Biopharmaceuticals
Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of...
by Raynovich Rod | Jun 10, 2018 | Biopharmaceuticals
Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature...
